InflaRx Revenue

Biotechnology Research • Jena, Thuringia, Germany • 51-100 Employees

InflaRx revenue & valuation

Annual revenue	$27,236
Revenue per employee	$1,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$87,155
Total funding	No funding

Key Contacts at InflaRx

Susan Fernandes

Director, Drug Safety Pharmacovigilance

Rooney Oldham

Director, Quality Assurance Gmp Usa

Brian Hennigan

Regional Account Director

Thomas Cash

Regional Sales Director

Ronald Rosenburg

Director Clinical Research And Development Dermatology

Yazhong Pei

Senior Director, Drug Discovery & Preclinical R&D

Niels Riedemann

Chief Executive Officer And Executive Director Of The Board

Renfeng Guo

Cso And Co-Founder

Trenton Charles Bruce

Human Resources Director

Ulrike Redlich

Director Clinical Trial Supplies

Company overview

Headquarters	Jena, Thuringia, Germany
Phone number	+493641508180
Website	inflarx.de
NAICS	541714
SIC	283
Founded	2007
Employees	51-100
Socials

InflaRx Email Formats

InflaRx uses 4 email formats. The most common is {first initial}.{last name} (e.g., j.doe@inflarx.de), used 62.8% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@inflarx.de	65.1%
{first name}.{last name}	john.doe@inflarx.de	34.9%

About InflaRx

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Director

Manager

Head

Employees by Department

InflaRx has 34 employees across 10 departments.

Departments

Number of employees

Funding Data

InflaRx has never raised funding before.

InflaRx Tech Stack

Discover the technologies and tools that power InflaRx's digital infrastructure, from frameworks to analytics platforms.

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

OpenSSL

Web server extensions

Java

Programming languages

CentOS

Operating systems

VideoJS

Video players

OWL Carousel

JavaScript libraries

Bootstrap

UI frameworks

Strato

Hosting

Microsoft 365

Frequently asked questions

InflaRx is located in Jena, Thuringia, DE.

You can reach InflaRx at +493641508180.

InflaRx generates an estimated annual revenue of $27,236. This revenue figure reflects the company's market position and business performance in its industry.

InflaRx has an estimated valuation of $87,155. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

InflaRx was founded in 2007, making it 19 years old. The company has established itself as a significant player in its industry over this time.

InflaRx has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.